Target Group's Cash Drops to $5,914 as Losses Double and Debt Defaults
CBDY sits 71% above its 52-week low of $0.001 on elevated volume (2.7× avg).
Summary
Target Group's Q2 2026 filing reveals cash of just $5,914, a net loss that doubled to $790,168, and a $7.3 million related-party loan in default — a sharp deterioration from the prior quarter.
Key Events · Earnings and Guidance · CBDY
-
Cash Nearly Exhausted
Cash fell to $5,914 as of June 30, 2026, from $100,410 at December 31, 2025. Total cash and restricted cash is only $14,006.
-
Net Loss More Than Doubles
Six-month net loss was $790,168, up from $327,983 in the prior-year period, driven by higher interest expense and lower gross profit.
-
Related-Party Loan in Default
The $7,334,333 CLI loan is in default and classified as a current liability. No payments were made during the period, and terms are under renegotiation.
-
Working Capital Deficit Widens
Working capital deficit increased to $11,232,219 from $11,052,097 at year-end, reflecting growing current liabilities.
Analysis · CBDY · Life Sciences
Target Group's second-quarter report shows a rapidly deteriorating financial position. Cash has fallen to just $5,914, down from $100,410 at year-end, while the six-month net loss more than doubled to $790,168. The company's working capital deficit widened to $11.2 million, and its related-party CLI loan of $7.3 million is now in default and due on demand. With only $14,006 in total cash and restricted cash, the company's ability to continue operations without immediate financing is severely constrained. The going-concern warning from the prior quarter is now backed by concrete numbers showing the runway is nearly exhausted.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CBDY was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $740.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.